Reduced antiretroviral drug susceptibility among patients with primary HIV infection

JAMA

Volumn 282, Issue 12, 1999, Pages 1142-1149

  Little, Susan J ^a,i   Daar, Eric S ^d   D'Aquila, Richard T ^f   Keiser, Philip H ^e   Connick, Elizabeth ^g   Whitcomb, Jeannette M ^h   Hellmann, Nicholas S ^h   Petropoulos, Christos J ^h   Sutton, Lorraine ^f   Pitt, Jacqui A ^d   Rosenberg, Eric S ^f   Koup, Richard A ^e   Walker, Bruce D ^f   Richman, Douglas D ^a,b,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h MONOGRAM BIOSCIENCES   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 0033615280     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.12.1142     Document Type: Article

References (40)

1. Weverling CJ, Lange JM, Jurriaans S, et al. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS. 1998;12:F117-F122.
2. Miller V, Phillips A, Rottmann C, et al. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J Infect Dis. 1998;177: 1521-1532.
3. Rey D, Hughes M, Pi JT, Winters M, Merigan TC, Katzenstein DA. HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:203-208.
4. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med. 1995;122: 401-408.
5. Erice A, Mayers DL, Strike DG, et al. Primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med. 1993;328:1163-1165.
6. Conway B, Montessori V, Rouleau D, et al. Primary lamivudine resistance in acute/early human immunodeficiency virus infection. Clin Infect Dis. 1999; 28:910-911.
7. Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. J Infect Dis. 1997;175:1502-1506.
8. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998;339:307-311.
9. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
10. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739.
11. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet. 1999;353:863-868.
12. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1998;280:78-86.
13. + T-cell responses associated with control of viremia. Science. 1997;278: 1447-1450.
14. Hirsch MS, Conway B, D'Aquila RT, et al. Anti-retroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA. 1998;279:1984-1991.
15. Piketty C, Race E, Castiel P, et al. Efficacy of a five-drug combination including rltonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS. 1999;13: F71-F77.
16. Harrigan R, Hogg R, Yip B, et al. Baseline resistance profile predicts response to ritonavir/ saquinavir therapy in a community setting. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 24-27, 1998; San Diego, Calif. Abstract 1-78.
17. Kozal MJ, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med. 1996;2:753-759
18. Goudsmit J, De Ronde A, Ho DD, Perelson AS. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J Virol. 1996;70:5662-5664.
19. Harrigan PR, Bloor S, Larder BA. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol. 1998; 72:3773-3778.
20. Martinez-Plcado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol. 1999;73:3744-3752.
21. Centers for Disease Control and Prevention. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep. 1998;47:1-33.
22. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996;125:257-264.
23. Vanhems P, Allard R, Cooper DA, et al. Acute human immunodeficiency virus type 1 disease as a mononucleosis-like illness: is the diagnosis too restrictive? Clin Infect Dis. 1997;24:965-970.
24. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med. 1991;324:961-964.
25. Clark SJ, Saag MS, Decker WD, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med. 1991; 324:954-960.
26. Hellman N, Johnson P, Petropoulos C. Validation of the performance characteristics of a novel, rapid phenotypic drug susceptibility assay, PhenoSense HIV. In: Program and abstracts of the 3rd International Workshop on Drug Resistance and Treatment Strategies; June 23-26, 1999; San Diego, Calif. Abstract 51.
27. Deeks SC, Hellmann NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis. 1999;179:1375-1381.
28. Parkin NT, Lie YS, Hellmann N, et al. Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus (HIV)-1 triple combination therapy. ; Infect Dis. 1999;180:865-870.
29. Miller MD, Wulfsohn MS, Margot NA, et al. Retrospective analysis of baseline susceptibility to adefovir dipivoxil is predictive of virological response in GS-96-408. In: Program and abstracts of the 3rd International Workshop on Drug Resistance and Treatment Strategies; June 23-26,1999; San Diego, Calif. Abstract 106.
30. Skowron G, Whitcomb J, Wesley M, et al. Viral load response to the addition of lamivudine correlates with phenotypic susceptibility to lamivudine and the presence of T215Y/F in the absence of M184V. In: Program and abstracts of the 3rd International Workshop on Drug Resistance and Treatment Strategies; June 23-26, 1999; San Diego, Calif. Abstract 81.
31. Parkin NT, Deeks SC, Grant RM, McGuire K, Hellmann NS, Petropoulos CJ. Emergence of HIV-1 with reduced drug susceptibility during four-drug salvage therapy. In: Program and abstracts of the 3rd International Workshop on Drug Resistance and Treatment Strategies; June 23-26, 1999; San Diego, Calif. Abstract 98.
32. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994;68:1660-1666.
33. Yerly S, Schockmel G, Bru JP, Hirschel B, Perrin L. Frequency of transmission of drug-resistant variants in individuals with primary HIV-1 infection. In: Program and abstracts of the XII International Conference on AIDS; June 28-July 3, 1998; Geneva, Switzerland. Abstract 32280.
34. Gómez-Cano M, Rubio A, Puig T, et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS. 1998; 12:1015-1020.
35. Hecht F, Kahn J, Dillon B, Chesney M, Grant R. Transmission of protease inhibitor resistant HIV-1 to a recently infected antiretroviral naive man: the UCSF-Options Primary HIV Project. In: Program and abstracts of the XII International Conference on AIDS; June 28-July 3, 1998; Geneva, Switzerland. Abstract 32288.
36. Imrie A, Carr A, Duncombe C, et al. Primary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year. J Infect Dis. 1996;174:195-198.
37. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995;171:1411-1419.
38. Daar E, Keerasuntonpong A, Pitt J, Bai J, Nichols S. Highly active antiretroviral therapy (HAART) vs non-HAART for primary HIV infection (PHIV). In: Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 640.
39. Huang W, Paxinos E, Petropoulos C, Whitcomb J. Measuring moderate differences in baseline NNRTI susceptibility. In: Program and abstracts of the 3rd International Workshop on Drug Resistance and Treatment Strategies; June 23-26, 1999; San Diego, Calif. Abstract 88.
40. Huang W, Limoli K, Sartoris M, Petropoulos CJ, Whitcomb J. Complex interactions involving multiple amino acid substitutions alter non-nucleoside reverse transcriptase inhibitor susceptibility. In: Program and abstracts of the 3rd International Workshop on Drug Resistance and Treatment Strategies; June 23-26, 1999; San Diego, Calif. Abstract 73.